Skip to main content

Advertisement

SpringerLink
Log in

Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation

  • Intra-abdominal Infections, Hepatitis, and Gastroenteritis (T Steiner, Section Editor)
  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

The incidence of end-stage liver disease (ESLD) is increasing and many of these patients may be considered for orthotopic liver transplantation. As patients with ESLD are at risk of a number of infections, infectious disease physicians should be aware of the management of these infections in order to provide optimal patient care and ensure transplantation success. We present a review of the literature pertaining to infectious disease considerations in the liver transplant candidate. It highlights several topics with recent developments including the management of hepatitis C virus infection prior to transplantation, treatment of hepatitis B virus infection, colonization and infection with multidrug resistant organisms, and management of spontaneous bacterial peritonitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. U.S. Census Bureau. Deaths: final data for 2013. National vital statistics reports. Hyattsville: National Center for Health Statistics; 2014.

    Google Scholar 

  2. Kim WR, Lake JR, Smith M, et al. OPTN/SRTR 2013 annual data report: liver. 2015

  3. Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144–65. Guidelines for evaluating pre-transplant liver candidates.

    Article  PubMed  Google Scholar 

  4. Fischer SA, Lu K, Infectious AST. Screening of donor and recipient in solid organ transplantation. Am J Transplant. 2013;4:9–21. Guidelines for evaulating pre-transplant liver candidates.

    Article  Google Scholar 

  5. Yehia BR, Blumberg EA. Mycobacterium tuberculosis infection in liver transplantation. Liver Transpl. 2010;16:1129–35.

    Article  PubMed  Google Scholar 

  6. Sidhu A, Verma G, Humar A, Kumar D. Outcome of latent tuberculosis infection in solid organ transplant recipients over a 10-year period. Transplantation. 2014;98:1–5.

    Article  Google Scholar 

  7. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant. 2013;13 Suppl 3:24–40.

    Article  PubMed  Google Scholar 

  8. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol. 2005;16:1758–74.

    Article  PubMed  Google Scholar 

  9. Vucicevic D, Carey EJ, Blair JE. Coccidioidomycosis in liver transplant recipients in an endemic area. Am J Transplant. 2011;11:111–9.

    Article  CAS  PubMed  Google Scholar 

  10. Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis. 2009;49:1411–23.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Rubin LG, Levin MJ, Ljungman P, et al. IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2013;2014:58.

    Google Scholar 

  12. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002;35:680–7.

    Article  PubMed  Google Scholar 

  13. Berenguer M. Natural history of recurrent hepatitis C. Liver Transpl. 2002;8:S14–8.

    Article  PubMed  Google Scholar 

  14. Burra P, De Martin E, Zanetto A, et al. HCV and liver transplantation: where do we stand? Transpl Int. 2015;7(12):1606–16. A detailed review of HCV treatment strategies pre- and post-transplant.

    Google Scholar 

  15. Dickson RC, Caldwell SH, Ishitani MB, et al. Clinical and histologic patterns of early graft failure due to recurrent hepatitis C in four patients after liver transplantation. Transplantation. 1996;61:701–5.

    Article  CAS  PubMed  Google Scholar 

  16. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32:673–84.

    Article  CAS  PubMed  Google Scholar 

  17. Hézode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)—NCT01514890. J Hepatol. 2013;59:434–41.

    Article  PubMed  Google Scholar 

  18. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection. N Engl J Med. 2002;347:975–82.

    Article  CAS  PubMed  Google Scholar 

  19. Bota S, Sporea I, Sirli R, et al. Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review. World J Hepatol. 2013;5:120–6.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42:255–62.

    Article  CAS  PubMed  Google Scholar 

  21. Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013;57:1752–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Davis GL, Al E. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–54. Current standard of practice for treatment of HCV in the USA with frequent updates.

    Article  Google Scholar 

  23. Pawlotsky J-M, Al E. EASL recommendations on treatment of hepatitis C 2014. ILC 2014 London. 2014;63:199–236. Current standard of practice for treatment of HCV in Europe.

    Google Scholar 

  24. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014.

  25. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–59. Seminal trial on treating HCV in patients with advanced liver disease.

    Article  CAS  PubMed  Google Scholar 

  26. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–82. Seminal trial on treating HCV in patients with advanced liver disease.

    Article  PubMed  Google Scholar 

  27. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280–8.

    Article  PubMed  Google Scholar 

  28. Flamm SL. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: preliminary results of a prospective, multicenter study. In: AASLD. 2014

  29. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med. 2008;149:399–403.

    Article  PubMed  Google Scholar 

  30. Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT. Post-transplant survival is improved for hepatitis c recipients who are rna negative at time of liver transplantation. Transpl. Int. 2015

  31. Rutter K, Stättermayer AF, Beinhardt S, et al. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther. 2015;41:1–11.

    Article  Google Scholar 

  32. Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis c virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730–40.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Verna EC, O’Leary JG. Hepatitis C treatment in patients on the liver transplant waiting list. Curr Opin Organ Transpl. 2015;20:242–50.

    Article  CAS  Google Scholar 

  34. Berenguer M, Aguilera V, Rubín A, Ortíz C, Jimenez M, Prieto M. Comparison of two non-contemporaneous HCV-liver transplant cohorts: strategies to improve the efficacy of antiviral therapy. J Hepatol. 2012;56:1310–6.

    Article  CAS  PubMed  Google Scholar 

  35. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014;371:2375–82.

    Article  PubMed  Google Scholar 

  36. Charlton MR, Gane EJ, Manns MP, et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective, multicenter study. Hepatology. 2013;58:108–17.

    Article  Google Scholar 

  37. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014;46:923–7.

    Article  CAS  PubMed  Google Scholar 

  38. Curry MP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100–7. Seminal trial on preventing post-transplant HCV recurrence.

    Article  CAS  PubMed  Google Scholar 

  39. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384:241–8.

    Article  PubMed  Google Scholar 

  40. Richterman A, Sawinski D, Reese PP, et al. An assessment of HIV-infected patients dying in care for deceased organ donation in a United States urban center. Am J Transplant. 2015;15:2105–16.

    Article  CAS  PubMed  Google Scholar 

  41. Miro JM, Stock P, Teicher E, Duclos-Vallée J-C, Terrault N, Rimola A. Outcome and management of HCV/HIV coinfection pre- and post-liver transplantation. A 2015 update. J Hepatol. 2015;62:701–11.

    Article  PubMed  Google Scholar 

  42. Boyarsky BJ, Durand CM, Palella FJ, Segev DL. Challenges and clinical decision-making in HIV-to-HIV transplantation: insights from the HIV literature. Am J Transplant. 2015;15:2023–30.

    Article  CAS  PubMed  Google Scholar 

  43. Lok ASF, McMahon BJ. AASLD Practice Guideline. Chronic hepatitis B: update 2009. Hepatology. 2009;50(31):661–2.

    Article  PubMed  Google Scholar 

  44. Fung J. Management of chronic hepatitis B before and after liver transplantation. World J Hepatol. 2015;7:1421–6.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Liaw Y-F, Sung JJY, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–31.

    Article  CAS  PubMed  Google Scholar 

  46. Chang TT, Liaw YF, Wu SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–93.

    Article  CAS  PubMed  Google Scholar 

  47. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2011;9:274–6.

    Article  CAS  PubMed  Google Scholar 

  48. Campos-Varela I, Castells L, Buti M, et al. Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIG and nucleoside analogues? Ann Hepatol. 2011;10:180–7.

    CAS  PubMed  Google Scholar 

  49. Fung J, Chan S-C, Cheung C, et al. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. Am J Gastroenterol. 2013;108:942–8. Highlights the importance of adequate pre-transplant HBV treatment.

    Article  CAS  PubMed  Google Scholar 

  50. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl. 2005;11:402–9.

    Article  PubMed  Google Scholar 

  51. Johnson LE, D’Agata EMC, Paterson DL, et al. Pseudomonas aeruginosa bacteremia over a 10-year period: multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis. 2009;11:227–34.

    Article  CAS  PubMed  Google Scholar 

  52. Van Duin D, Van Delden C. Multidrug-resistant gram-negative bacteria infections in solid organ transplantation. Am J Transplant. 2013;13:31–41. A nice review of the issue of drug resistance in transplant patients.

    Article  PubMed  Google Scholar 

  53. Ziakas PD, Pliakos EE, Zervou FN, Knoll BM, Rice LB, Mylonakis E. MRSA and VRE colonization in solid organ transplantation: a meta-analysis of published studies. Am J Transplant. 2014;14:1887–94.

    Article  CAS  PubMed  Google Scholar 

  54. Gearhart M, Martin JE, Rudich S, et al. Consequences of vancomycin-resistant Enterococcus in liver transplant recipients: a matched control study. Clin Transpl. 2005;19:711–6.

    Google Scholar 

  55. Russell DL, Flood A, Zaroda TE, et al. Outcomes of colonization with MRSA and VRE among liver transplant candidates and recipients. Am J Transplant. 2008;8:1737–43.

    Article  CAS  PubMed  Google Scholar 

  56. Vasoo S, Barreto JN, Tosh PK. Emerging issues in gram-negative bacterial resistance. Mayo Clin Proc. 2015;90:395–403.

    Article  PubMed  Google Scholar 

  57. Won SY, Munoz-Price LS, Lolans K, Hota B, Weinstein RA, Hayden MK. Emergence and rapid regional spread of klebsiella Pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis. 2011;53:532–40.

    Article  CAS  PubMed  Google Scholar 

  58. Bergamasco MD, Barroso Barbosa M, de Oliveira GD, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transpl Infect Dis. 2012;14:198–205.

    Article  CAS  PubMed  Google Scholar 

  59. Kalpoe JS, Sonnenberg E, Factor SH, et al. Mortality associated with carbapenem-resistant klebsiella pneumoniae infections in liver transplant recipients. Liver Transpl. 2012;18:468–74.

    Article  PubMed  Google Scholar 

  60. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943–50.

    Article  CAS  PubMed  Google Scholar 

  61. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56:2108–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Saidel-Odes L, Polachek H, Peled N, et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect Control Hosp Epidemiol. 2012;33:14–9.

    Article  PubMed  Google Scholar 

  63. Huttner B, Haustein T, Uçkay I, et al. Decolonization of intestinal carriage of extended-spectrum Β-lactamase-producing Enterobacteriaceae with oral colistin and neomycin: a randomized, double-blind, placebo-controlled trial. J Antimicrob Chemother. 2013;68:2375–82.

    CAS  PubMed  Google Scholar 

  64. Cheng VC, Chen JH, Tai JW, et al. Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature. BMC Infect Dis. 2014;14:514.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Singh R, Van Nood E, Nieuwdorp M, Paterson DL, Potoski BA, Van Dam B, et al. Donor feces infusion for eradication of extended spectrum beta-lactamase producing Escherichia coli in a patient with end stage renal disease. Clin Microbiol Infect. 2014;20:10–1.

    Article  Google Scholar 

  66. Bryce E, Wong T, Forrester L, et al. Nasal photodisinfection and chlorhexidine wipes decrease surgical site infections: a historical control study and propensity analysis. J Hosp Infect. 2014;88:89–95. Highlights a novel technique for surgical decolonization.

    Article  CAS  PubMed  Google Scholar 

  67. Botwin GJ, Morgan TR. Bacterial infections in cirrhosis. Hepatol Int. 2014;8:467–74.

    Article  PubMed  Google Scholar 

  68. Piroth L, Pechino A, Di Martino V, et al. Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis: a two-year observational study. BMC Infect Dis. 2014;14:287.

    Article  PubMed Central  PubMed  Google Scholar 

  69. Merli M, Lucidi C, Di Gregorio V, et al. The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey. PLoS One 2015; 10

  70. Piano S, Fasolato S, Salinas F, et al. The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: results of a randomized controlled clinical trial. Hepatology. 2015;62(2):S6241. Highlights issue of bacterial resistance and adequacy of empiric antibiotic choices for spontaneous bacterial peritonitis.

    Google Scholar 

  71. Runyon BA. AASLD PRACTICE GUIDELINE management of adult patients with ascites due to cirrhosis: update 2012. Hepatology. 2013;57:1651–3.

    Article  PubMed  Google Scholar 

  72. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;50:1321.

    Article  Google Scholar 

  73. Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35:140–8.

    Article  PubMed  Google Scholar 

  74. Fernández J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology. 2012;55:1551–61.

    Article  PubMed  Google Scholar 

  75. Berti T, Benoni G, Miglioli PA, Al. E. Intestinal antibacterial activity of a new rifamycin derivative: compound L-105. Chemioterapia 1982; suppl 4:106–111.

  76. Fiorentino F, Simioli F, Conte M, Postiglione A, Cinque F, Santaniello A. Open study on the antidiarrheal effectiveness of the L 105 compound. Chemioterapia. 1984;3:132–5.

    CAS  PubMed  Google Scholar 

  77. DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal gram-negative flora and enterococci. Clin Microbiol Infect. 2004;10:1009–11.

    Article  CAS  PubMed  Google Scholar 

  78. Hanouneh MA, Hanouneh IA, Hashash JG, et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J Clin Gastroenterol. 2012;46:709–15.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, BC, Canada

    Allison Mah & Alissa Wright

Authors
  1. Allison Mah
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alissa Wright
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alissa Wright.

Ethics declarations

Conflict of Interest

Alissa Wright and Allison Mah declare no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Additional information

This article is part of the Topical Collection on Intra-abdominal Infections, Hepatitis, and Gastroenteritis

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mah, A., Wright, A. Infectious Considerations in the Pre-Transplant Evaluation of Cirrhotic Patients Awaiting Orthotopic Liver Transplantation. Curr Infect Dis Rep 18, 4 (2016). https://doi.org/10.1007/s11908-015-0514-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11908-015-0514-5

Keywords

Search

Navigation